In whatever form biosimilar legislation might take, patent holders will need to review their patent portfolios carefully
Jonathan Davies, PhD, Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Advertisement
Articles by Jonathan Davies, PhD, Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Advertisement
Latest Updated Articles
- Follow-on Biologics: A Patent Litigation Perspective
Published: August 22nd 2009 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Novo Nordisk’s Bloomington Plant Receives FDA OAI Designation Following Contamination and Compliance Issues
2
Pharma Pulse: Kaiser Permanente Strike Escalates, Takeda Partners with Nabla Bio, and FDA Flags Novo Nordisk Bloomington Site
3
How Healthcare Organizations Can Balance Federal and State AI Regulations
4
Why Regulatory Sandboxes Offer a Safe Space for AI Innovation in Healthcare
5
